Study on Utidelone's Efficacy in HER-2 Negative Advanced Breast Cancer
A randomized controlled study is evaluating the efficacy of Utidelone Capsule versus Utidelone Injection in combination with Capecitabine for HER-2 negative advanced breast cancer.
Phase III
Oncology / Breast Cancer
Status
Negative
Sponsor
Beijing Biostar Pharmaceuticals Co., Ltd.
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The ongoing trial of Utidelone in HER-2 negative advanced breast cancer could significantly influence its market positioning and competitive landscape. Positive outcomes may lead to increased investment and strategic focus on breast cancer therapies, impacting overall portfolio strategies.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor the trial results for Progression-Free Survival metrics and any subsequent regulatory filings.
Related companies & assets
Assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.